Versor Investments LP recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
1120 Avenue Of The Americas New York, NY 10036
As of the latest 13F report, the guru’s equity portfolio contained 689 stocks valued at a total of $1.16Bil. The top holdings were
According to GuruFocus data, these were Versor Investments LP’s top five trades of the quarter.
Biohaven Pharmaceutical Holding Co Ltd
The guru sold out of their 698,793-share investment in NYSE:BHVN. Previously, the stock had a 3.9% weight in the equity portfolio. Shares traded for an average price of $148.2 during the quarter.
On 01/30/2023, Biohaven Pharmaceutical Holding Co Ltd traded for a price of $14.08 per share and a market cap of $1.01Bil. The stock has returned -89.71% over the past year.
GuruFocus gives the company a financial strength rating of 2 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Biohaven Pharmaceutical Holding Co Ltd has a EV-to-Ebitda ratio of -15.28 and a price-sales ratio of 1.13.
Duke Realty Corp
The guru sold out of their 1,847,962-share investment in NYSE:DRE. Previously, the stock had a 3.89% weight in the equity portfolio. Shares traded for an average price of $58.56 during the quarter.
On 01/30/2023, Duke Realty Corp traded for a price of $48.2 per share and a market cap of $18.56Bil. The stock has returned -14.25% over the past year.
GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Duke Realty Corp has a price-earnings ratio of 19.44, a price-book ratio of 2.94, a price-earnings-to-growth (PEG) ratio of 1.87, a EV-to-Ebitda ratio of 15.77 and a price-sales ratio of 16.85.
The price-to-GF Value ratio is 0.99, earning the stock a GF Value rank of 5.
CMC Materials Inc
The guru sold out of their 513,822-share investment in NAS:CCMP. Previously, the stock had a 3.44% weight in the equity portfolio. Shares traded for an average price of $173.19 during the quarter.
On 01/30/2023, CMC Materials Inc traded for a price of $173.69 per share and a market cap of $4.97Bil. The stock has returned 19.91% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, CMC Materials Inc has a price-earnings ratio of 45.47, a price-book ratio of 5.26, a price-earnings-to-growth (PEG) ratio of 7.71, a EV-to-Ebitda ratio of 17.64 and a price-sales ratio of 4.00.
The price-to-GF Value ratio is 1.00, earning the stock a GF Value rank of 5.
Mandiant Inc
The guru sold out of their 4,008,877-share investment in NAS:MNDT. Previously, the stock had a 3.35% weight in the equity portfolio. Shares traded for an average price of $22.66 during the quarter.
On 01/30/2023, Mandiant Inc traded for a price of $22.98 per share and a market cap of $5.40Bil. The stock has returned 26.47% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 3 out of 10.
In terms of valuation, Mandiant Inc has a price-earnings ratio of 6.55, a price-book ratio of 3.96, a EV-to-Ebitda ratio of -17.04 and a price-sales ratio of 10.30.
The price-to-GF Value ratio is 1.07, earning the stock a GF Value rank of 3.
Sierra Oncology Inc
The guru sold out of their 1,579,751-share investment in NAS:SRRA. Previously, the stock had a 3.33% weight in the equity portfolio. Shares traded for an average price of $54.99 during the quarter.
On 01/30/2023, Sierra Oncology Inc traded for a price of $54.99 per share and a market cap of $1.34Bil. The stock has returned 178.71% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Sierra Oncology Inc has a price-book ratio of 5.00 and a EV-to-Ebitda ratio of -10.50.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
